CAMP logo

CAMPCalamp Corp.

$4.32
$0.15
(3.60%)
Today
Updated: 01:35 PM EDT
Reported EarningsMay 7
Mkt Cap$216.53M
Vol29,972.00
53

Neutral Sentiment

How do you feel about CAMP?

News
all
press releases
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
More News
News Placeholder
Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1%
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369...
MarketBeat
News Placeholder
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 414,235 shares, a decrease of 14.2% from the March 15th total of 483,060 shares. Based on an average daily trading...
MarketBeat
News Placeholder
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw
Rodman & Renshaw upgraded CAMP4 Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat
News Placeholder
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs) and provided an update on its lead central nervous system (CNS) program...
MarketBeat
News Placeholder
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts
CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...
MarketBeat
News Placeholder
Camp4 Therapeutics Earnings Review: Q4 Summary
read more...
Benzinga
News Placeholder
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know
CAMP4 Therapeutics Corporation (CAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
<
...
1
>

Advertisement|Remove ads.